Mitsubishi UFJ Asset Management’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,396
| Closed | -$245K | – | 1640 |
|
|
2025
Q4 | $245K | Sell |
3,396
-4,080
| -55% | -$264K | ﹤0.01% | 989 |
|
|
2025
Q3 | $326K | Buy |
7,476
+15
| +0.2% | +$606 | ﹤0.01% | 933 |
|
|
2025
Q2 | $212K | Buy |
7,461
+1,326
| +22% | +$39.5K | ﹤0.01% | 973 |
|
|
2025
Q1 | $181K | Buy |
6,135
+514
| +9% | +$16K | ﹤0.01% | 965 |
|
|
2024
Q4 | $171K | Sell |
5,621
-3,292
| -37% | -$138K | ﹤0.01% | 1010 |
|
|
2024
Q3 | $409K | Sell |
8,913
-844
| -9% | -$36.6K | ﹤0.01% | 878 |
|
|
2024
Q2 | $399K | Sell |
9,757
-29,606
| -75% | -$849K | ﹤0.01% | 879 |
|
|
2024
Q1 | $1M | Sell |
39,363
-1,803
| -4% | -$28.3K | ﹤0.01% | 804 |
|
|
2023
Q4 | $394K | Buy |
41,166
+15,654
| +61% | +$105K | ﹤0.01% | 946 |
|
|
2023
Q3 | $163K | Buy |
25,512
+1,403
| +6% | +$12.1K | ﹤0.01% | 1042 |
|
|
2023
Q2 | $267K | Buy |
24,109
+1,108
| +5% | +$13.9K | ﹤0.01% | 1001 |
|
|
2023
Q1 | $353K | Buy |
23,001
+1,063
| +5% | +$23.4K | ﹤0.01% | 966 |
|
|
2022
Q4 | $444K | Buy |
21,938
+2,035
| +10% | +$30.3K | ﹤0.01% | 920 |
|
|
2022
Q3 | $325K | Buy |
19,903
+348
| +2% | +$6.66K | ﹤0.01% | 967 |
|
|
2022
Q2 | $284K | Buy |
+19,555
| New | +$291K | ﹤0.01% | 1002 |
|
Other funds holding RNAM
Mitsubishi UFJ Asset Management's RNAM Position: Q1 2026 in Review
Mitsubishi UFJ Asset Management sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 3,396 shares — an estimated $245K sold.
Mitsubishi UFJ Asset Management first reported a position in RNAM in Q2 2022 and held it in 15 quarters. The position peaked at $1M in Q1 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Mitsubishi UFJ Asset Management reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Mitsubishi UFJ Asset Management sold 3,396 Avidity Biosciences shares in Q1 2026, an estimated $245K.
- Mitsubishi UFJ Asset Management first reported a position in Avidity Biosciences in Q2 2022 and held it in 15 quarters.
- Mitsubishi UFJ Asset Management's Avidity Biosciences position peaked at $1M in Q1 2024.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Mitsubishi UFJ Asset Management's 13F filing for Q1 2026, filed 12 May 2026.